Arena Pharmaceuticals, Inc. Equity-NMS: ARNA

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

$99.93

What is the share price of Arena Pharmaceuticals, Inc. today?

Arena Pharmaceuticals, Inc. (ARNA) share price as of January 1, 1970, is $. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Arena Pharmaceuticals, Inc.?

Yes, Indian Investors can invest in the Arena Pharmaceuticals, Inc. (ARNA) Share by opening an international trading account with Angel One.

How can I purchase Arena Pharmaceuticals, Inc. shares in India?

Purchasing Arena Pharmaceuticals, Inc. (ARNA) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Arena Pharmaceuticals, Inc. (ARNA) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Arena Pharmaceuticals, Inc.?

Yes, you can purchase fractional shares of Arena Pharmaceuticals, Inc. (ARNA) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Arena Pharmaceuticals, Inc.?

The market capitalization of Arena Pharmaceuticals, Inc. on January 1, 1970, is $0.

What documents are required to invest in Arena Pharmaceuticals, Inc. stocks?

In order to invest in Arena Pharmaceuticals, Inc. (ARNA) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. The Company's clinical programs include Etrasimod, which is an oral, selective sphingosine 1-phosphate (S1P), receptor modulator, designed to provide systemic and local cell modulation by targeting S1P receptor subtypes one, four and five. Olorinab, an orally available, potent, peripherally acting, selective, full agonist of the CB2 receptor, is an internally discovered investigational drug candidate. APD418 is an adrenergic receptor (AdrR) antagonist and cardiac myotrope designed to regulate myofilament calcium sensitivity in order to improve contractility without inducing the adverse events associated with available inotropes. Temanogrel is a peripherally acting and selective 5HT2a inverse agonist designed to inhibit serotonin (5-HT) mediated amplification of platelet aggregation and vasoconstriction.